We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
NeuroPace (NPCE) Moves 6.3% Higher: Will This Strength Last?
Read MoreHide Full Article
NeuroPace, Inc. (NPCE - Free Report) shares soared 6.3% in the last trading session to close at $18.12. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 17.4% gain over the past four weeks.
NeuroPace scored a strong price increase on investors’ optimism surrounding the company’s impending first quarter financial result, which is slated to release on May 12. Per the Zacks Consensus Estimate, the company’s first quarter revenue is projected to be $21.6 million and loss per share is pegged at 19 cents.
This company is expected to post quarterly loss of $0.19 per share in its upcoming report, which represents a year-over-year change of +9.5%. Revenues are expected to be $21.62 million, down 4% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For NeuroPace, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on NPCE going forward to see if this recent jump can turn into more strength down the road.
NeuroPace is part of the Zacks Medical - Instruments industry. Steris (STE - Free Report) , another stock in the same industry, closed the last trading session 0.7% higher at $214.46. STE has returned -2.9% in the past month.
For Steris, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $2.89. This represents a change of +5.5% from what the company reported a year ago. Steris currently has a Zacks Rank of #3 (Hold).
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
NeuroPace (NPCE) Moves 6.3% Higher: Will This Strength Last?
NeuroPace, Inc. (NPCE - Free Report) shares soared 6.3% in the last trading session to close at $18.12. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 17.4% gain over the past four weeks.
NeuroPace scored a strong price increase on investors’ optimism surrounding the company’s impending first quarter financial result, which is slated to release on May 12. Per the Zacks Consensus Estimate, the company’s first quarter revenue is projected to be $21.6 million and loss per share is pegged at 19 cents.
This company is expected to post quarterly loss of $0.19 per share in its upcoming report, which represents a year-over-year change of +9.5%. Revenues are expected to be $21.62 million, down 4% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For NeuroPace, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on NPCE going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
NeuroPace is part of the Zacks Medical - Instruments industry. Steris (STE - Free Report) , another stock in the same industry, closed the last trading session 0.7% higher at $214.46. STE has returned -2.9% in the past month.
For Steris, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $2.89. This represents a change of +5.5% from what the company reported a year ago. Steris currently has a Zacks Rank of #3 (Hold).